Forma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Forma Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0489
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Forma Therapeutics Inc (Forma) is a drug discovery and development company that discovers and develops new transformative cancer therapeutics. The company develops technologies to identify the initial molecules that provide drug discovery program. It offers research in the areas of tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. FORMA’s drug development process includes computational and medicinal chemistry, parallel synthesis, X-ray crystallography, and relevant biology studies. The company collaborates with biotechnology companies, pharmaceuticals and biomedicine companies and research institutes for its research and development activities. It operates offices in Watertown and Branford, the US. FORMA is headquartered in Watertown, Massachusetts, the US.

Forma Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forma Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Forma Therapeutics Raises US$10 Million In Venture Financing 11
Partnerships 12
Ubiquigent Enters into Development Agreement with Forma Therapeutics 12
Forma Therapeutics Enters into Agreement with Arpeggio Biosciences 13
Celgene Enters into Agreement with Forma Therapeutics 14
ZoBio and Domainex Enter into Agreement with Forma Therapeutics 15
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 16
Forma Therapeutics Partners With Celgene 17
Forma Therapeutics Enters Into Agreement With Celgene 18
Forma Therapeutics Enters Into Co-Development Agreement With TGen Drug Development 20
FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 21
FORMA Therapeutics Enters Into R&D Agreement With Boehringer Ingelheim 22
Licensing Agreements 23
Forma Therapeutics and HitGen Enter into Licensing Agreement 23
Forma Therapeutics Enters into Licensing Agreement with University of Oxford 24
Forma Therapeutics Enters Into Licensing Agreement With Netherlands Cancer Institute 25
Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 26
Moffitt Cancer Center Enters into Option for Licensing Agreement with Forma Therapeutics 27
Forma Therapeutics Inc – Key Competitors 28
Forma Therapeutics Inc – Key Employees 29
Forma Therapeutics Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Corporate Communications 31
Apr 09, 2018: FORMA Therapeutics Appoints Tim Clackson As Board Director 31
Nov 14, 2017: FORMA Therapeutics Appoints Christine Bellon, Ph.D., J.D., General Counsel and Corporate Secretary 32
Government and Public Interest 33
Feb 21, 2017: FORMA Therapeutics Awarded Grant from Michael J. Fox Foundation for Parkinson’s Research 33
Product News 34
Apr 05, 2018: FORMA Therapeutics Achieves Key Objective in Collaboration with Celgene to Advance a Novel Protein Homeostasis Oncology/Immuno-Oncology Program 34
Other Significant Developments 35
Mar 13, 2017: FORMA Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forma Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forma Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Forma Therapeutics Raises US$10 Million In Venture Financing 11
Ubiquigent Enters into Development Agreement with Forma Therapeutics 12
Forma Therapeutics Enters into Agreement with Arpeggio Biosciences 13
Celgene Enters into Agreement with Forma Therapeutics 14
ZoBio and Domainex Enter into Agreement with Forma Therapeutics 15
Forma Therapeutics Expands Discovery Agreement with Cancer Research Technology 16
Forma Therapeutics Partners With Celgene 17
Forma Therapeutics Enters Into Agreement With Celgene 18
Forma Therapeutics Enters Into Co-Development Agreement With TGen Drug Development 20
FORMA Therapeutics Enters Into Co-Development Agreement With Janssen Biotech 21
FORMA Therapeutics Enters Into R&D Agreement With Boehringer Ingelheim 22
Forma Therapeutics and HitGen Enter into Licensing Agreement 23
Forma Therapeutics Enters into Licensing Agreement with University of Oxford 24
Forma Therapeutics Enters Into Licensing Agreement With Netherlands Cancer Institute 25
Janssen Biotech Exercises Option For Licensing Agreement With Forma Therapeutics 26
Moffitt Cancer Center Enters into Option for Licensing Agreement with Forma Therapeutics 27
Forma Therapeutics Inc, Key Competitors 28
Forma Therapeutics Inc, Key Employees 29
Forma Therapeutics Inc, Other Locations 30

List of Figures
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Forma Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Forma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vallourec Sa:企業の戦略・SWOT・財務分析
    Vallourec Sa - Strategy, SWOT and Corporate Finance Report Summary Vallourec Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Kuwait Energy Plc:石油・ガス:M&Aディール及び事業提携情報
    Summary Kuwait Energy Plc (Kuwait Energy) is an independent oil and gas company that carries out exploration, appraisal, development and production of hydrocarbons. The company operates wide range of oil and gas assets in Middle East and North Africa (MENA) region. It has assets across Egypt, Yemen, …
  • Karus Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Karus Therapeutics Ltd (Karus) is a drug development company that designs and develops cancer therapies. The company offers small molecule drugs with immunotherapy for the treatment of hematological and solid tumors. Its pipeline products include KA2507 and KA2237 inhibitors. Karus’ KA2507 i …
  • Nampak Limited:企業の戦略・SWOT・財務情報
    Nampak Limited - Strategy, SWOT and Corporate Finance Report Summary Nampak Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • The Boston Beer Co Inc (SAM):企業の財務・戦略的SWOT分析
    The Boston Beer Co Inc (SAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Biocurv Medical Instruments, Inc.:企業の戦略・SWOT・財務情報
    Biocurv Medical Instruments, Inc. - Strategy, SWOT and Corporate Finance Report Summary Biocurv Medical Instruments, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Senzime AB (SEZI):企業の財務・戦略的SWOT分析
    Summary Senzime AB (Senzime) is a medical device company that develops patient-oriented monitoring systems. The company's product include TetraGraph monitor, CliniSenz analyzer, and Onzurf probe. Its TetraGraph monitor stimulates, measures, analyzes and displays muscle function in surgical patients …
  • American Cancer Society Inc:企業の戦略的SWOT分析
    American Cancer Society Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Isuzu Motors Ltd (7202):企業の財務・戦略的SWOT分析
    Isuzu Motors Ltd (7202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Melkior Resources Inc. (MKR):企業の財務・戦略的SWOT分析
    Melkior Resources Inc. (MKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Ajinomoto Co Inc (2802):製薬・医療:M&Aディール及び事業提携情報
    Summary Ajinomoto Co Inc (Ajinomoto) is a food products company that focuses on foods, bioscience fine chemicals and pharmaceuticals and health. It carries out research and development and production of seasonings, and provides Knorr cup soup products, processed foods, edible oils, sweeteners, bever …
  • HEINEKEN USA Incorporated:企業の戦略・SWOT・財務情報
    HEINEKEN USA Incorporated - Strategy, SWOT and Corporate Finance Report Summary HEINEKEN USA Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • The AES Corporation:発電所・企業SWOT分析
    The AES Corporation – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • FuelCell Energy Inc (FCEL)-エネルギー分野:企業M&A・提携分析
    Summary FuelCell Energy, Inc. (FuelCell Energy) is an integrated fuel cell company that designs, manufactures, installs, operates, and services stationary fuel cell power plants for distributed power generation. It offers proprietary fuel cell products based on Direct FuelCell (DFC) carbonate fuel c …
  • Awilco LNG ASA (ALNG):企業の財務・戦略的SWOT分析
    Summary Awilco LNG ASA (Awilco LNG) a subsidiary of Awilhelmsen AS is an oil and gas company that provides LNG transportation programs. The company owns and operates LNG vessels intended for international trading. It offers LNG value chain such as liquefaction, production, regasification, transporta …
  • Johnson & Johnson (JNJ):医療機器:M&Aディール及び事業提携情報
    Summary Johnson & Johnson (J&J) researches and develops, and manufactures and sells a range of pharmaceutical products, medical devices and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; …
  • Deutsche Borse AG:企業のM&A・事業提携・投資動向
    Deutsche Borse AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Deutsche Borse AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Panoptes Pharma GesmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Panoptes Pharma GesmbH (Panoptes Pharma) is a biotech company that develops small molecule based therapies to treat severe eye diseases. The company also develops products in the therapeutic areas of uveitis, viral conjunctivitis, and further indications. It concentrates on a new treatment f …
  • ADNOC Distribution (ADNOCDIST):石油・ガス:M&Aディール及び事業提携情報
    Summary ADNOC Distribution, a subsidiary of Abu Dhabi National Oil Co (ADNOC), markets and distributes petroleum products, natural gas and other products. The company mainly operates in the retail transportation fuels, wholesale fuels, and forecourt convenience store markets in Abu Dhabi and the nor …
  • The Mauritius Commercial Bank Limited:企業の戦略・SWOT・財務分析
    The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report Summary The Mauritius Commercial Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆